According to Zacks, “Greenbrook TMS Inc. is a provider of Transcranial Magnetic Stimulation therapy, an FDA-cleared, non-invasive therapy for the treatment of Major Depressive Disorder and other mental health disorders, principally in the United States. Greenbrook TMS Inc. is based in TORONTO. “
Several other brokerages have also recently issued reports on GBNH. Canaccord Genuity Group cut Greenbrook TMS to a “buy” rating in a research note on Monday, February 7th. Stifel Nicolaus reduced their price target on shares of Greenbrook TMS from C$19.00 to C$10.00 in a research report on Tuesday, May 17th. Clarus Securities lowered their price objective on shares of Greenbrook TMS from C$8.25 to C$7.50 in a research report on Monday, April 4th. Finally, Bloom Burton reissued a “buy” rating on shares of Greenbrook TMS in a report on Monday, April 4th. One analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Buy” and an average target price of $13.04.
Shares of GBNH stock traded down $0.09 during trading hours on Monday, hitting $2.32. 700 shares of the company were exchanged, compared to its average volume of 13,063. The stock has a market capitalization of $41.30 million, a price-to-earnings ratio of -1.57 and a beta of 2.29. Greenbrook TMS has a one year low of $2.01 and a one year high of $13.89. The business’s 50-day simple moving average is $2.65 and its two-hundred day simple moving average is $3.74. The company has a debt-to-equity ratio of 4.31, a quick ratio of 0.95 and a current ratio of 0.95.
Greenbrook TMS (NASDAQ:GBNH – Get Rating) last announced its quarterly earnings data on Friday, May 13th. The company reported ($0.44) earnings per share (EPS) for the quarter. The firm had revenue of $13.07 million for the quarter, compared to analyst estimates of $11.70 million. Greenbrook TMS had a negative net margin of 46.27% and a negative return on equity of 157.80%. During the same quarter in the previous year, the company earned ($0.56) EPS. As a group, analysts anticipate that Greenbrook TMS will post -1.26 EPS for the current fiscal year.
Several hedge funds and other institutional investors have recently modified their holdings of GBNH. Royal Bank of Canada grew its holdings in Greenbrook TMS by 243.1% in the 3rd quarter. Royal Bank of Canada now owns 6,848 shares of the company’s stock worth $51,000 after buying an additional 4,852 shares in the last quarter. AM Investment Strategies LLC bought a new stake in Greenbrook TMS during the 1st quarter valued at $90,000. Rockefeller Capital Management L.P. acquired a new position in Greenbrook TMS during the 3rd quarter worth $109,000. Bank of Montreal Can bought a new position in shares of Greenbrook TMS in the first quarter worth $123,000. Finally, AdvisorShares Investments LLC increased its holdings in shares of Greenbrook TMS by 365.5% during the fourth quarter. AdvisorShares Investments LLC now owns 64,214 shares of the company’s stock valued at $281,000 after purchasing an additional 50,418 shares during the period. Institutional investors and hedge funds own 16.73% of the company’s stock.
About Greenbrook TMS (Get Rating)
Greenbrook TMS Inc, together with its subsidiaries, controls and operates a network of outpatient mental health services centers in the United States. Its centers specialize in the provision of transcranial magnetic stimulation (TMS) therapy, an FDA-cleared non-invasive therapy for the treatment of major depressive disorder and other mental health disorders, as well as related psychiatric services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Greenbrook TMS Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Greenbrook TMS and related companies with MarketBeat.com’s FREE daily email newsletter.